YZJ-3058
/ Yangtze River Pharmaceutical Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 11, 2021
[VIRTUAL] YZJ-3058: an oral, potent, and highly selective bruton’s tyrosine kinase (BTK) inhibitor for the treatment of B cell lymphoma and RA
(AACR 2021)
- "YZJ-3058 is an orally bioavailable covalent BTK inhibitor with high kinase selectivity. YZJ-3058 displayed suitable preclinical pharmacokinetic and promising pharmacodynamic characteristics. YZJ-3058 is expected to conduct clinical trials simultaneously in China and the USA in 2021."
Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • EGFR
1 to 1
Of
1
Go to page
1